MorphoSys

MorphoSys Settles Patent Lawsuit with Janssen and Genmab
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
CP Wire
MorphoSys
Janssen
Genmab
daratumumab
patents
Flag link:
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
MorphoSys
Janssen
Genmab
patent lawsuits
patents
Darazalex
Flag link:
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
CP Wire
MorphoSys
Janssen
Genmab
patents
Flag link:
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
MorphoSys
Janssen
Genmab
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
With no partner, MorphoSys drops MOR202 in myeloma
With no partner, MorphoSys drops MOR202 in myeloma
Biopharma Dive
MorphoSys
earnings
anti-CD3 antibody
MOR202
Flag link:
Novartis to Pay as Much as $1 Billion for Rights to Skin Drug
Novartis to Pay as Much as $1 Billion for Rights to Skin Drug
Yahoo/Bloomberg
Novartis
Galapagos
MorphoSys
MOR106
atopic dermatitis
Flag link:
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Fierce Pharma
JNJ
Tremfya
MorphoSys
Janssen
Crohn's Disease
clinical trials
Flag link:
In knockout IPO offerings, MorphoSys and Surface Oncology haul combined $316M in upsized deals
In knockout IPO offerings, MorphoSys and Surface Oncology haul combined $316M in upsized deals
Endpoints
IPOs
MorphoSys
Surface Oncology
NASDAQ
Flag link:
Galapagos peaks as AbbVie hype builds, Shorts target Bavarian, MorphoSys makes GPCR play
Galapagos peaks as AbbVie hype builds, Shorts target Bavarian, MorphoSys makes GPCR play
Fierce Biotech
Galapagos
AbbVie
Bavarian Nordic
Intec Pharma
MorphoSys
Flag link:
MorphoSys: That Celgene-abandoned cancer drug isn't dead yet
MorphoSys: That Celgene-abandoned cancer drug isn't dead yet
Fierce Biotech
MorphoSys
Celgene
MOR202
Flag link:
MorphoSys tanks after Celgene walks away from $818M pact
MorphoSys tanks after Celgene walks away from $818M pact
Fierce Biotech
MorphoSys
Celgene
Multiple Myeloma
Flag link:
MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting
MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting
Yahoo/PR Newswire
MorphoSys
Xencor
MOR208
chronic lymphocytic leukemia
leukemia
Flag link:
US FDA grants fast tract status to MorphoSys's MOR208 programme to treat DLBCL
US FDA grants fast tract status to MorphoSys's MOR208 programme to treat DLBCL
PharmaBiz
diffuse large B-cell lymphoma
lymphoma
MorphoSys
MOR208
Flag link:
Novartis aims to show strength with muscle wasting drug
Novartis aims to show strength with muscle wasting drug
Yahoo/Reuters
muscle wasting
Novartis
sporadic inclusion body myositis
BYM338
MorphoSys
Flag link:
MorphoSys Plans to Raise Spending on Immunotherapy Treatments
MorphoSys Plans to Raise Spending on Immunotherapy Treatments
Bloomberg
MorphoSys
immunotherapy
Flag link:
Watch Out for These 3 Biotech Companies
Watch Out for These 3 Biotech Companies
Motley Fool
Biogen Idec
Biocad
Amgen
M&A
Celgene
MorphoSys
Tecfidera
Flag link:
MorphoSys Rises on $818 Million Drug Alliance
MorphoSys Rises on $818 Million Drug Alliance
Bloomberg
MorphoSys
MOR202
Celgene
Multiple Myeloma
Flag link:
Is This GlaxoSmithKline's Next Big Blockbuster?
Is This GlaxoSmithKline's Next Big Blockbuster?
Motley Fool
rheumatoid arthritis
GSK
Humira
AbbVie
MOR103
MorphoSys
Flag link:
Biotech Portfolio Update: 2012 Summary And 2013 Outlook
Biotech Portfolio Update: 2012 Summary And 2013 Outlook
Seeking Alpha
Arqule
Array Biopharma
Celldex
Aveo Pharmaceutical
Curis
Exelixis
MorphoSys
Genmab
Novartis
Incyte
Seattle Genetics
YM BioSciences
Flag link:

Pages